Know their risk, protect their future.
Every patient has a risk of developing cancer. A simple genetic test can reveal which patients would benefit from additional screening and care, so you can take action, help improve outcomes, and help more patients than ever before.
MyRisk® with RiskScore® is the all-in-one hereditary cancer test, risk assessment, and care plan.
Strive towards standard of care
Access to genetic risk assessment means access to the life-changing benefits of increased screening and early detection. ACR and SBI now recommend that all women, especially black women and those of Ashkenazi Jewish descent, should be evaluated for breast cancer risk no later than age 30, so that those at higher risk can be identified and can benefit from supplemental screening.
Help improve outcomes with high-risk care plans
Among patients who qualify for genetic testing, 56%1 will require a medical management change due to their individualized cancer risk. Knowing your patients’ risk allows more informed clinical recommendations, such as increased screening, risk-reducing interventions, and family member screening.
1Myriad Internal Data based on OBGYN and Primary Care Settings, Sept 2019
Meet Kim, a breast cancer survivor and mother of two. MyRisk® with RiskScore® gave Kim additional screening options that ultimately caught an elusive cancer not visible on her mammogram.
MyRisk is more than a test
Most hereditary cancer tests only produce positive or negative results. MyRisk takes this a step further, including the MyRisk Management Tool in every report. This easy-to-use guide breaks down everything you need to know about using these results to inform your patient’s personal care plan today and in the future.
Give your patients a complete answer
When it comes to assessing breast cancer risk, MyRisk with RiskScore® offers personalized care plans that your practice can use to help improve patient outcomes.
What’s RiskScore?
For patients who receive a negative test result, RiskScore is a component of the MyRisk test that expands beyond Tyrer-Cuzick, providing a more accurate and personalized estimate of their likelihood to develop breast cancer over the next 5 years and lifetime. This personalized result guides patients and providers to make more confident and informed medical decisions for managing cancer risk including supplemental screening such as breast MRI.
For patients of all ancestries
As the only hereditary cancer test designed for patients of all ancestries, MyRisk with RiskScore helps you give more patients answers about their cancer risks than ever before.
More direction for more patients
56%1 of patients tested with MyRisk qualify for a change in their medical management vs. approximately 10%1 expected if tested with other labs.
1Myriad Internal Data based on OBGYN and Primary Care Settings, Sept 2019
A partner to your practice
Integrating hereditary cancer risk testing into your practice has never been easier with our second-to-none expert support and easy-to-use MyRisk Management Tool. These solutions simplify interpreting results and implementing personalized care plans, which may include increased screening and surveillance.
